Literature DB >> 33914121

Immunoglobulin deficiencies in treated patients suffering from rheumatoid arthritis.

Sara Kaestner1,2, Hans-Juergen Wolff3, Rolf Braeuer4, Peter Kaestner3.   

Abstract

Immunoglobulins and antibodies to immunoglobulins (autoimmunoglobulins) have been identified to be implicated in the pathogenesis of rheumatoid arthritis (RA). Immunoglobulin deficiencies have been suggested to account for the increased risk of infections in RA patients. This study was carried out to determine the prevalence of immunoglobulin deficiencies in patients with RA and the identification of putative contributing factors. Immunoglobulin levels in blood samples of patients with rheumatoid arthritis were evaluated by an immunonephelometric assay. Demographic and disease related data (including age, sex, smoking habits, disease duration and activity, inflammatory markers) were assessed, and associations were identified by regression analysis. 539 patients were enrolled between 2011 and 2013. The most common immunoglobulin (Ig) deficiencies were those of IgM (24.5%) and IgG (19.9%). Most frequent deficiencies of subclasses were observed for IgG1 (42.3%), followed by IgG4 (10.4%), IgG2 (7.2%), and IgG3 (5.4%). Regression analyses revealed that deficiencies of IgM, IgG, IgG1, and IgG2 were more prevalent in older patients. In addition, smoking was associated with IgG2 deficiency, and IgA deficiency was associated with female sex. Occurrence of infections was significantly increased in patients with IgG, IgG2, and IgG4 deficiencies. RA patients displayed high rates of IgG and IgM deficiencies. In consequence, the assessment of immunoglobulin status should precede the application of immune modulating drugs to prevent a potential risk of infectious diseases. Prospective studies are needed to investigate the influence of immune modulating drugs on IgG and IgG subclass levels.

Entities:  

Keywords:  Antirheumatic agents; IgG deficiency; Immunoglobulin G; Immunoglobulins; Infections; Rheumatoid arthritis

Mesh:

Year:  2021        PMID: 33914121     DOI: 10.1007/s00296-021-04871-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  Serum immunoglobulins in rheumatoid arthritis.

Authors:  H N Claman; D Merrill
Journal:  J Lab Clin Med       Date:  1966-05

2.  Serum IgG subclass concentrations in healthy adults: a study using monoclonal antisera.

Authors:  M A French; G Harrison
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

3.  Quantification of IgG subclasses in sera of normal adults and healthy children between 4 and 12 years of age.

Authors:  M van der Giessen; E Rossouw; T A van Veen; E van Loghem; B J Zegers; P C Sander
Journal:  Clin Exp Immunol       Date:  1975-09       Impact factor: 4.330

Review 4.  Rheumatoid arthritis.

Authors:  D M Lee; M E Weinblatt
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

5.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

Authors:  Michele F Doran; Cynthia S Crowson; Gregory R Pond; W Michael O'Fallon; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2002-09

6.  Predictors of infection in rheumatoid arthritis.

Authors:  Michele F Doran; Cynthia S Crowson; Gregory R Pond; W Michael O'Fallon; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2002-09

7.  Aclidinium bromide provides long-acting bronchodilation in patients with COPD.

Authors:  P Chanez; P S Burge; R Dahl; J Creemers; A Chuchalin; R Lamarca; E Garcia Gil
Journal:  Pulm Pharmacol Ther       Date:  2009-08-14       Impact factor: 3.410

8.  Crossed immunoelectrophoresis and electroimmunoassay of human IgG subclasses.

Authors:  V A Oxelius
Journal:  Acta Pathol Microbiol Scand C       Date:  1978-06

9.  Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Authors:  A Strangfeld; M Eveslage; M Schneider; H J Bergerhausen; T Klopsch; A Zink; J Listing
Journal:  Ann Rheum Dis       Date:  2011-07-25       Impact factor: 19.103

10.  Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.

Authors:  G Wells; J-C Becker; J Teng; M Dougados; M Schiff; J Smolen; D Aletaha; P L C M van Riel
Journal:  Ann Rheum Dis       Date:  2008-05-19       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.